JP2008516964A5 - - Google Patents

Download PDF

Info

Publication number
JP2008516964A5
JP2008516964A5 JP2007536876A JP2007536876A JP2008516964A5 JP 2008516964 A5 JP2008516964 A5 JP 2008516964A5 JP 2007536876 A JP2007536876 A JP 2007536876A JP 2007536876 A JP2007536876 A JP 2007536876A JP 2008516964 A5 JP2008516964 A5 JP 2008516964A5
Authority
JP
Japan
Prior art keywords
pyrazol
phenyl
ethyl
compound
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007536876A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008516964A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2005/036801 external-priority patent/WO2006044528A1/en
Publication of JP2008516964A publication Critical patent/JP2008516964A/ja
Publication of JP2008516964A5 publication Critical patent/JP2008516964A5/ja
Pending legal-status Critical Current

Links

JP2007536876A 2004-10-15 2005-10-14 ホスホジエステラーゼ４阻害剤としてのピラゾール誘導体 Pending JP2008516964A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US61872504P 2004-10-15 2004-10-15
PCT/US2005/036801 WO2006044528A1 (en) 2004-10-15 2005-10-14 Pyrazole derivatives as phosphodiesterase 4 inhibitors

Publications (2)

Publication Number Publication Date
JP2008516964A JP2008516964A (ja) 2008-05-22
JP2008516964A5 true JP2008516964A5 (enExample) 2008-12-04

Family

ID=35759321

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007536876A Pending JP2008516964A (ja) 2004-10-15 2005-10-14 ホスホジエステラーゼ４阻害剤としてのピラゾール誘導体

Country Status (7)

Country Link
US (2) US7432266B2 (enExample)
EP (1) EP1799673A1 (enExample)
JP (1) JP2008516964A (enExample)
CN (1) CN101166733A (enExample)
AU (1) AU2005295753A1 (enExample)
CA (1) CA2584317A1 (enExample)
WO (1) WO2006044528A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1910307A1 (en) * 2005-06-27 2008-04-16 Exelixis, Inc. Pyrazole based lxr modulators
US20070254913A1 (en) * 2006-04-19 2007-11-01 Dunn Robert F Phosphodiesterase 4 inhibitors
WO2008029829A1 (en) * 2006-09-06 2008-03-13 Kyorin Pharmaceutical Co., Ltd. Pyrazolopyridine derivative and phosphodiesterase (pde) inhibitor containing the same as active ingredient
US7825261B2 (en) * 2006-12-05 2010-11-02 National Taiwan University Indazole compounds
AU2007333194A1 (en) 2006-12-08 2008-06-19 Exelixis, Inc. LXR and FXR modulators
FR2916758B1 (fr) * 2007-06-04 2009-10-09 Sanofi Aventis Sa Derives de 1-benzylpyrazole, leur preparation et leur application en therapeutique
US20090047243A1 (en) * 2007-07-17 2009-02-19 Richard Rickles Combinations for the treatment of b-cell proliferative disorders
CA2694983A1 (en) * 2007-07-17 2009-01-22 Combinatorx, Incorporated Treatments of b-cell proliferative disorders
US20100009934A1 (en) * 2008-06-09 2010-01-14 Combinatorx, Incorporated Beta adrenergic receptor agonists for the treatment of b-cell proliferative disorders
WO2014117947A1 (en) 2013-02-04 2014-08-07 Grünenthal GmbH 4-amino substituted condensed pyrimidine compounds as pde4 inhibitors
CN104230890A (zh) * 2013-06-19 2014-12-24 信诺凯（北京）化工有限公司 吡啶-2-胺衍生物及其制法和药物组合物与用途
CA2921308A1 (en) 2013-08-16 2015-02-19 Universiteit Maastricht Treatment of cognitive impairment with pde4 inhibitor
WO2015161830A1 (en) * 2014-04-25 2015-10-29 Sunshine Lake Pharma Co., Ltd. Heteroaromatic derivatives and pharmaceutical applications thereof
US10975081B2 (en) * 2015-07-23 2021-04-13 Glaxosmithkline Intellectual Property Development Limited Substituted fused pyrazole compounds and their use as LRRK2 inhibitors
CN106188027B (zh) * 2015-09-02 2020-10-20 广东东阳光药业有限公司 芳杂环类衍生物及其在药物中的应用
US9845314B2 (en) * 2015-09-11 2017-12-19 Boehrnger Ingelheim International Gmbh Pyrazolyl-substituted heteroaryls and their use as medicaments
CN116249692B (zh) * 2020-09-28 2024-08-23 四川科伦博泰生物医药股份有限公司 吡唑类化合物及其制备方法和用途
WO2025201504A1 (en) * 2024-03-29 2025-10-02 Beigene (Suzhou) Co., Ltd. Kat6 inhibitors

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4193926A (en) * 1974-03-20 1980-03-18 Schering Aktiengesellschaft 4-(Polyalkoxy phenyl)-2-pyrrolidones
DE2413935A1 (de) * 1974-03-20 1975-10-16 Schering Ag 4-(polyalkoxy-phenyl)-2-pyrrolidone
DE2834114A1 (de) * 1978-08-01 1980-02-14 Schering Ag Polyalkoxyphenylpyrrolidone iii, verfahren zu ihrer herstellung und ihre verwendung
DE3921593A1 (de) * 1989-06-28 1991-01-10 Schering Ag Verfahren zur racemattrennung von 4-aryl-2-oxo-pyrrolidin-3-carbonsaeure-ester
US5935978A (en) * 1991-01-28 1999-08-10 Rhone-Poulenc Rorer Limited Compounds containing phenyl linked to aryl or heteroaryl by an aliphatic- or heteroatom-containing linking group
PT100441A (pt) 1991-05-02 1993-09-30 Smithkline Beecham Corp Pirrolidinonas, seu processo de preparacao, composicoes farmaceuticas que as contem e uso
AU2869092A (en) 1991-10-11 1993-05-03 Smithkline Beecham Corporation Heterocyclic 3-phenylpyrrolidin-2-ones, their preparation and use for the manufacture of a medicament for inhibiting tumor necrosis factor production
ES2102036T3 (es) 1992-06-15 1997-07-16 Celltech Therapeutics Ltd Derivados con grupo fenilo trisustituido utilizados como inhibidores selectivos de la fosfodiesterasa iv.
US5814651A (en) * 1992-12-02 1998-09-29 Pfizer Inc. Catechol diethers as selective PDEIV inhibitors
TW263495B (enExample) 1992-12-23 1995-11-21 Celltech Ltd
CA2186371A1 (en) * 1994-03-25 1995-10-05 Robert T. Foster Enhancement of the efficacy of dihydropyridines by deuteration
US6334997B1 (en) * 1994-03-25 2002-01-01 Isotechnika, Inc. Method of using deuterated calcium channel blockers
PT758233E (pt) 1994-04-21 2004-04-30 Schering Ag Inibidores pde iv para o tratamento da esclerose multipla
GB9412383D0 (en) 1994-06-21 1994-08-10 Celltech Ltd Chemical compound
DE19518082A1 (de) * 1995-05-17 1996-11-21 Merck Patent Gmbh 4(-Arylaminomethylen)-2,4-dihydropyrazol-3-one
WO1997012884A1 (en) * 1995-10-04 1997-04-10 Fmc Corporation Herbicidal 6-heterocyclic indazole derivatives
DE19601938A1 (de) 1996-01-12 1997-07-17 Schering Ag Neue Phosphodiesteraseinhibitoren
ES2201299T3 (es) 1996-06-25 2004-03-16 Pfizer Inc. Derivados sustituidos de indazol y su uso como inhibidores de fosfodiesterasa (pde) de tipo iv y factor de necrosis tumoral (tnf)`.
JPH1072415A (ja) 1996-06-26 1998-03-17 Nikken Chem Co Ltd ３−アニリノ−２−シクロアルケノン誘導体
GB9622386D0 (en) * 1996-10-28 1997-01-08 Sandoz Ltd Organic compounds
US6235736B1 (en) * 1997-06-24 2001-05-22 Nikken Chemicals Co., Ltd. 3-anilino-2-cycloalkenone derivatives
US6403597B1 (en) * 1997-10-28 2002-06-11 Vivus, Inc. Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation
CA2309175A1 (en) * 1997-11-04 1999-05-14 Pfizer Products Inc. Therapeutically active compounds based on indazole bioisostere replacement of catechol in pde4 inhibitors
AU4308300A (en) * 1999-05-03 2000-11-17 Dr. Reddy's Research Foundation Pyrazoles having antiinflammatory activity
JP2001039954A (ja) * 1999-05-24 2001-02-13 Tomono Agrica Co Ltd ヘテロ環誘導体
CA2392931A1 (en) 1999-12-03 2001-06-07 Pfizer Products Inc. Heterocyclo-alkylsulfonyl pyrazole derivatives as anti-inflammatory/analgesic agents
US6372777B1 (en) * 1999-12-23 2002-04-16 Icos Corporation Cyclic AMP-specific phosphodiesterase inhibitors
US6258833B1 (en) * 1999-12-23 2001-07-10 Icos Corporation Cyclic AMP-specific phosphodiesterase inhibitors
GB0003257D0 (en) * 2000-02-11 2000-04-05 Darwin Discovery Ltd Heterocyclic compounds and their therapeutic use
EP1265861A2 (en) 2000-03-16 2002-12-18 Inflazyme Pharmaceuticals, Ltd. Benzylated pde4 inhibitors
WO2001081332A2 (en) * 2000-04-25 2001-11-01 Pharmacia Corporation 2-fluorobenzenesulfonyl compounds for the treatment of inflammation
WO2002045749A2 (en) 2000-11-02 2002-06-13 Research Foundation Of City University Of New York Methods for stimulating nervous system regeneration and repair by inhibition phosphodiesterase type 4
US6495154B1 (en) * 2000-11-21 2002-12-17 Vivus Inc. On demand administration of clomipramine and salts thereof to treat premature ejaculation
US6673818B2 (en) * 2001-04-20 2004-01-06 Pharmacia Corporation Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation
ATE402164T1 (de) * 2001-04-26 2008-08-15 Eisai R&D Man Co Ltd Stickstoffhaltige verbindung mit kondensiertem ring und pyrazolylgruppe als substituent und medizinische zusammensetzung davon
US20030162824A1 (en) * 2001-11-12 2003-08-28 Krul Elaine S. Methods of treating or preventing a cardiovascular condition using a cyclooxygenase-1 inhibitor
AU2003238667B2 (en) * 2002-04-05 2006-07-20 Cadila Healthcare Limited 4-(heterocyclyl)-benzenesulfoximine compounds for the treatment of inflammation
UA79804C2 (en) * 2002-07-03 2007-07-25 Janssen Pharmaceutica Nv Cck-1 receptor modulators
WO2004033432A1 (ja) * 2002-10-09 2004-04-22 Ssp Co., Ltd. 抗真菌活性を有する新規ピラゾール化合物
US7226930B2 (en) * 2003-04-18 2007-06-05 Memory Pharmaceutical Corporation Phosphodiesterase 4 inhibitors
HUP0304101A3 (en) * 2003-12-22 2008-10-28 Sanofi Aventis Pyrazole derivatives, process for producing them, their use, pharmaceutical compositions containing them and their intermediates
US20070254913A1 (en) * 2006-04-19 2007-11-01 Dunn Robert F Phosphodiesterase 4 inhibitors

Similar Documents

Publication Publication Date Title
JP2008516964A5 (enExample)
KR102491308B1 (ko) Cyp11a1 (시토크롬 p450 모노옥시게나제 11a1) 억제제로서 피란 유도체
RU2005135562A (ru) Производные пиразола в качестве ингибиторов фосфодиэстеразы 4
US7211594B2 (en) Indazole compounds and compositions thereof as JNK inhibitors and for the treatment of diseases associated therewith
JP3490716B2 (ja) 炎症治療用３，４−置換ピラゾール
ES2385659T3 (es) Derivados de pirazol para tratar VIH
RU2009149696A (ru) 5-замещенные индазолы в качестве ингибиторов киназы
RU2455288C2 (ru) Соединения и композиции 5-(4-(галогеналкокси)фенил)пиримидин-2-амина в качестве ингибиторов киназ
JP2015520752A5 (enExample)
JP3628946B2 (ja) トリアゾール及びイミダゾール誘導体
RU2011146872A (ru) Производные пролина в качестве ингибиторов катепсина
RU2011127232A (ru) Апоптоз-индуцирующие средства для лечения рака и иммунных и аутоиммунных заболеваний
JP2016519156A5 (enExample)
RU2013133800A (ru) Селективные к bcl-2 агенты, вызывающие апоптоз, для лечения рака и иммунных заболеваний
JP2007039461A5 (enExample)
JP2017524026A5 (enExample)
JP4597524B2 (ja) アミノアルキル置換されたアゼチジン、ピロリジン、ピペリジン、およびアゼパンのアミド
RU2011115111A (ru) Замещенные пирролидин-2-карбоксамиды
JP2014511869A5 (enExample)
EP1680114A2 (en) Triazole compounds and uses related thereto
CA2670605A1 (en) Substituted arylpyrazoles
WO2007123953A2 (en) Phosphodiesterase 4 inhibitors
JP2010513379A5 (enExample)
RU2019123319A (ru) Пиразолопиримидины и способы их применения
AR046788A1 (es) Antagonistas del receptor peptido relacionado con el gen de calcitonina